


CureMetrix Delivers Artificial Intelligence to Optimize Halo Dx Clinical Operations and Efficacy in Mammography Imaging

LA JOLLA, CA, USA, October 1, 2019 /EINPresswire.com/ -- CureMetrix, a healthcare technology company that develops Al-driven software for radiology, announced today a software license and collaboration agreement with HALO Dx to optimize the clinical operations and efficacy of mammography screening clinics across the nation.

CureMetrix received FDA-clearance for its workflow product <u>cmTriage™</u> and is currently conducting studies to expand its suite of AI solutions with <u>cmAssist®</u> to identify, mark and score anomalies in breast cancer screening.

In <u>studies published in the Journal of</u> <u>Digital Imaging</u>, cmAssist was able to demonstrate the ability to find cancers up to six years before first detection, and help radiologists improve their detection on average 27% with less than a 1% increase in recall rates. ¹



Further, in a study that included a head-to-head comparison with traditional computer aided detection (CAD) software, CureMetrix Al-driven CAD cmAssist was able to demonstrate 69% fewer false markings.²



We are pleased to complement the market leading services that Halo Dx provides – to help improve clinical outcomes, productivity and assist their radiologists to deliver better patient care."

Kevin Harris, CEO CureMetrix

"Our team of medical advisors has guided us through the creation of some of the strongest performing Al products in the industry," and said Kevin Harris, Chief Executive Officer of CureMetrix. "We are pleased to complement the market leading services that Halo Dx provides and to expand our portfolio of services with them to help improve clinical outcomes, productivity and assist their radiologists to deliver better patient care."

1 Watanabe, A.T., Lim, V., Vu, H.X. et al. J Digit Imaging (2019) 32: 625. https://doi.org/10.1007/s10278-019-00192-

About HALO Dx

HALO Dx is a highly differentiated rapid growth diagnostic technology company setting the new standard for patient experience and diagnostic insights in the medical imaging industry. Visit https://www.halodx.com/

About CureMetrix

CureMetrix is committed to the advancement of technology that improves cancer survival rates worldwide. With research that leverages artificial intelligence (AI) and deep learning to develop the next generation of medical image analysis, CureMetrix delivers technology that radiologists, healthcare systems and patients can confidently rely on. Visit https://curemetrix.com/

Media Contact: Dawn Anderson CureMetrix +1 858-345-6061 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.